DOCSLIB.ORG

Incorrect Email Address for Corresponding Author

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Incorrect Email Address for Corresponding Author Letters patients with nonsquamous non–small cell lung cancer in our Bristol-Myers Squibb Co Ltd, Eli Lilly Japan K. K., Ono Pharmaceutical Co Ltd, and cohort at the 6-week landmark analysis of progression-free sur- Taiho Pharmaceutical Co Ltd; lecture fees from Chugai Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, MSD K. K., and Pfizer Japan Inc; and research funding vival (PFS), with 43 of these patients having a PD-L1 TPS of less from Ono Pharmaceutical Co Ltd. Dr Nakagawa has received honoraria from than 50% and 11 a PD-L1 TPS of 50% or greater. These num- Astellas Pharma Inc, AstraZeneca K. K., Ayumi Pharmaceutical Corp, Boehringer bers are too small to allow detection of a statistically signifi- Ingelheim Japan Inc, Bristol-Myers Squibb Co Ltd, Chugai Pharmaceutical Co Ltd, cant difference in PFS in either subgroup between individu- Daiichi Sankyo Co Ltd, Eli Lilly Japan K. K., Kissei Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, MSD K. K., Novartis Pharma K. K., Ono Pharmaceutical Co Ltd, als with irAEs and those without irAEs. However, there was a Pfizer Japan Inc, Showa Yakuhin Kako Co Ltd, Sym Bio Pharmaceuticals Ltd, and nonsignificant finding of a longer PFS in patients with irAEs Taiho Pharmaceutical Co Ltd; research funding from AbbVie Inc, Astellas Pharma than in those without such events for the subgroups with either Inc, AstraZeneca K. K., Boehringer Ingelheim Japan Inc, Bristol-Myers Squibb Co Ltd, Daiichi Sankyo Co Ltd, Eisai Co Ltd, Eli Lilly Japan K. K., GlaxoSmithKline K. K., a low (hazard ratio, 0.58; 95% CI, 0.29-1.16; log-rank P = .12) Kyowa Hakko Kirin Co Ltd, Merck Serono Co Ltd, MSD K. K., Novartis Pharma K. K., or high (hazard ratio, 0.19; 95% CI, 0.008-2.05; log-rank P = .16) Ono Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Pfizer Japan Inc, Taiho PD-L1 TPS. Although further studies will be needed to con- Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd, and Yakult Honsha Co Ltd; firm these preliminary findings, they suggest that the occur- and consulting or advisory fees from Astellas Pharma Inc, Eli Lilly Japan K. K., and Ono Pharmaceutical Co Ltd. No other disclosures are reported. rence of irAEs may be predictive of nivolumab efficacy at least 1. Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse in part in a manner independent of the PD-L1 expression level events with nivolumab efficacy in non–small-cell lung cancer. JAMA Oncol. 2018; on tumor cells. 4(3):374-378. 2. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in Koji Haratani, MD advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17): Hidetoshi Hayashi, MD, PhD 1627-1639. Kazuhiko Nakagawa, MD, PhD Author Affiliations: Department of Medical Oncology, Kindai University Faculty CORRECTION of Medicine, Osaka-Sayama, Osaka, Japan. Incorrect Email Address for Corresponding Author: In the Research Letter titled Corresponding Author: Hidetoshi Hayashi, MD, PhD, Department of Medical “Breast Cancer With a Poor Prognosis Diagnosed After Screening Mammography Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, With Negative Results,” published online May 3, 2018, and in this issue of JAMA Osaka-Sayama, Osaka 589-8511, Japan ([email protected]). Oncology,1 Dr McCarthy’s email address was incorrect. In the Corresponding Au- Published Online: May 31, 2018. doi:10.1001/jamaoncol.2018.0751 thor portion of the Article Information section, her email address should have been Conflict of Interest Disclosures: Dr Haratani has received honoraria from Ono listed as “[email protected].” This article was corrected online. Pharmaceutical Co Ltd, as well as lecture fees from Pfizer Japan Inc, 1. McCarthy AM, Barlow WE, Conant EF, et al. Breast cancer with a poor AstraZeneca K. K., and Bristol-Myers Squibb Co Ltd. Dr Hayashi has received prognosis diagnosed after screening mammography with negative results honoraria from AstraZeneca K. K., Boehringer Ingelheim Japan Inc, [published online May 3, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.0352 1018 JAMA Oncology July 2018 Volume 4, Number 7 (Reprinted) jamaoncology.com © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021.
Load more

Recommended publications
  • Nilotinib in Patients with Chronic Myeloid Leukemia: STAT2 Trial in Japan
    Haematologica HAEMATOL/2018/194894 Version 3 Haematologica HAEMATOL/2018/194894 Version 3 Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan Naoto Takahashi, Kaichi Nishiwaki, Chiaki Nakaseko, Nobuyuki Aotsuka, Koji Sano, Chikako Ohwada, Jun Kuroki, Hideo Kimura, Michihide Tokuhira, Kinuko Mitani, Kazuhisa Fujikawa, Osamu Iwase, Kohshi Ohishi, Fumihiko Kimura, Tetsuya Fukuda, Sakae Tanosaki, Saori Takahashi, Yoshihiro Kameoka, Hiroyoshi Nishikawa, and Hisashi Wakita Disclosures: 1. This study was supported by research funding from Novartis Pharmaceuticals to N.T. 2. N.T reports grants from Novartis Pharmaceuticals, during the conduct of the study; grants and personal fees from Novartis Pharmaceuticals, grants and personal fees from Otsuka, grants and personal fees from Pfizer, personal fees from Bristol-Myers Squibb, outside the submitted work; K.N reports grants from Zenyaku Kogyo Company, Limited, grants from Chugai Pharmaceutical, grants from Novartis Pharma K.K., grants from Kyowa Hakko Kirin Co, Ltd, grants from Nippon Shinyaku Co, Ltd, outside the submitted work; C.N reports personal fees from Novartis, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Pfizer, grants and personal fees from Takeda pharmaceuticals, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Otsuka Pharmaceutical, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Asahi Kasei Pharma, grants and personal fees from Shionogi, personal fees from Shire, personal fees from Jannsen, personal fees from Celgene, outside the submitted work; M.T. reports personal fees from Bristol-Myers Squib, personal fees from Pfizer, outside the submitted work; K.M reports grants from Kyowa Hakko Kirin Co.
    [Show full text]
  • Factset-Top Ten-0521.Xlsm
    Pax International Sustainable Economy Fund USD 7/31/2021 Port. Ending Market Value Portfolio Weight ASML Holding NV 34,391,879.94 4.3 Roche Holding Ltd 28,162,840.25 3.5 Novo Nordisk A/S Class B 17,719,993.74 2.2 SAP SE 17,154,858.23 2.1 AstraZeneca PLC 15,759,939.73 2.0 Unilever PLC 13,234,315.16 1.7 Commonwealth Bank of Australia 13,046,820.57 1.6 L'Oreal SA 10,415,009.32 1.3 Schneider Electric SE 10,269,506.68 1.3 GlaxoSmithKline plc 9,942,271.59 1.2 Allianz SE 9,890,811.85 1.2 Hong Kong Exchanges & Clearing Ltd. 9,477,680.83 1.2 Lonza Group AG 9,369,993.95 1.2 RELX PLC 9,269,729.12 1.2 BNP Paribas SA Class A 8,824,299.39 1.1 Takeda Pharmaceutical Co. Ltd. 8,557,780.88 1.1 Air Liquide SA 8,445,618.28 1.1 KDDI Corporation 7,560,223.63 0.9 Recruit Holdings Co., Ltd. 7,424,282.72 0.9 HOYA CORPORATION 7,295,471.27 0.9 ABB Ltd. 7,293,350.84 0.9 BASF SE 7,257,816.71 0.9 Tokyo Electron Ltd. 7,049,583.59 0.9 Munich Reinsurance Company 7,019,776.96 0.9 ASSA ABLOY AB Class B 6,982,707.69 0.9 Vestas Wind Systems A/S 6,965,518.08 0.9 Merck KGaA 6,868,081.50 0.9 Iberdrola SA 6,581,084.07 0.8 Compagnie Generale des Etablissements Michelin SCA 6,555,056.14 0.8 Straumann Holding AG 6,480,282.66 0.8 Atlas Copco AB Class B 6,194,910.19 0.8 Deutsche Boerse AG 6,186,305.10 0.8 UPM-Kymmene Oyj 5,956,283.07 0.7 Deutsche Post AG 5,851,177.11 0.7 Enel SpA 5,808,234.13 0.7 AXA SA 5,790,969.55 0.7 Nintendo Co., Ltd.
    [Show full text]
  • Research and Development in Breast Ultrasound E
    E. Ueno, T. Shiina, M. Kubota, K. Sawai (Eds.) Research and Development in Breast Ultrasound E. Ueno, T. Shiina M. Kubota, K. Sawai (Eds.) Research and Development in Breast Ultrasound With 150 Figures, Including 37 in Color 1 3 Ei Ueno, M.D., Ph.D. Associate Professor, Department of Breast-Thyroid-Endocrine Surgery Institute of Clinical Medicine, University of Tsukuba 1-1-1 Tennodai, Tsukuba, Ibaraki 304-8573, Japan Tsuyoshi Shiina, Ph.D. Professor, Institute of Information Sciences and Electronics, University of Tsukuba 1-1-1 Tennodai, Tsukuba, Ibaraki 304-8573, Japan Mitsuhiro Kubota, M.D. Director of Yamachika Memorial Hospital 3-19-14 Koyawata, Odawara, Kanagawa 256-0815, Japan Kiyoshi Sawai, M.D. Associate Professor, Department of Endocrine & Breast Surgery Kyoto Prefectural University of Medicine 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-0841, Japan Cover Illustration: Madoka Momota Library of Congress Control Number: 2004116202 ISBN 4-431-40277-2 Springer-Verlag Tokyo Berlin Heidelberg New York This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broad- casting, reproduction on microfilms or in other ways, and storage in data banks. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and appli- cation thereof contained in this book.
    [Show full text]
  • Portfolio of Investments
    PORTFOLIO OF INVESTMENTS CTIVP® – Lazard International Equity Advantage Fund, September 30, 2020 (Unaudited) (Percentages represent value of investments compared to net assets) Investments in securities Common Stocks 97.6% Common Stocks (continued) Issuer Shares Value ($) Issuer Shares Value ($) Australia 6.9% Finland 1.0% AGL Energy Ltd. 437,255 4,269,500 Metso OYJ 153,708 2,078,669 ASX Ltd. 80,181 4,687,834 UPM-Kymmene OYJ 36,364 1,106,808 BHP Group Ltd. 349,229 9,021,842 Valmet OYJ 469,080 11,570,861 Breville Group Ltd. 153,867 2,792,438 Total 14,756,338 Charter Hall Group 424,482 3,808,865 France 9.5% CSL Ltd. 21,611 4,464,114 Air Liquide SA 47,014 7,452,175 Data#3 Ltd. 392,648 1,866,463 Capgemini SE 88,945 11,411,232 Fortescue Metals Group Ltd. 2,622,808 30,812,817 Cie de Saint-Gobain(a) 595,105 24,927,266 IGO Ltd. 596,008 1,796,212 Cie Generale des Etablissements Michelin CSA 24,191 2,596,845 Ingenia Communities Group 665,283 2,191,435 Electricite de France SA 417,761 4,413,001 Kogan.com Ltd. 138,444 2,021,176 Elis SA(a) 76,713 968,415 Netwealth Group Ltd. 477,201 5,254,788 Legrand SA 22,398 1,783,985 Omni Bridgeway Ltd. 435,744 1,234,193 L’Oreal SA 119,452 38,873,153 REA Group Ltd. 23,810 1,895,961 Orange SA 298,281 3,106,763 Regis Resources Ltd.
    [Show full text]
  • JPX-Nikkei Index 400 Constituents (Applied on August 31, 2021) Published on August 6, 2021 No
    JPX-Nikkei Index 400 Constituents (applied on August 31, 2021) Published on August 6, 2021 No. of constituents : 400 (Note) The No. of constituents is subject to change due to de-listing. etc. (Note) As for the market division, "1"=1st section, "2"=2nd section, "M"=Mothers, "J"=JASDAQ. Code Market Divison Issue Code Market Divison Issue 1332 1 Nippon Suisan Kaisha,Ltd. 3048 1 BIC CAMERA INC. 1417 1 MIRAIT Holdings Corporation 3064 1 MonotaRO Co.,Ltd. 1605 1 INPEX CORPORATION 3088 1 Matsumotokiyoshi Holdings Co.,Ltd. 1719 1 HAZAMA ANDO CORPORATION 3092 1 ZOZO,Inc. 1720 1 TOKYU CONSTRUCTION CO., LTD. 3107 1 Daiwabo Holdings Co.,Ltd. 1721 1 COMSYS Holdings Corporation 3116 1 TOYOTA BOSHOKU CORPORATION 1766 1 TOKEN CORPORATION 3141 1 WELCIA HOLDINGS CO.,LTD. 1801 1 TAISEI CORPORATION 3148 1 CREATE SD HOLDINGS CO.,LTD. 1802 1 OBAYASHI CORPORATION 3167 1 TOKAI Holdings Corporation 1803 1 SHIMIZU CORPORATION 3231 1 Nomura Real Estate Holdings,Inc. 1808 1 HASEKO Corporation 3244 1 Samty Co.,Ltd. 1812 1 KAJIMA CORPORATION 3254 1 PRESSANCE CORPORATION 1820 1 Nishimatsu Construction Co.,Ltd. 3288 1 Open House Co.,Ltd. 1821 1 Sumitomo Mitsui Construction Co., Ltd. 3289 1 Tokyu Fudosan Holdings Corporation 1824 1 MAEDA CORPORATION 3291 1 Iida Group Holdings Co.,Ltd. 1860 1 TODA CORPORATION 3349 1 COSMOS Pharmaceutical Corporation 1861 1 Kumagai Gumi Co.,Ltd. 3360 1 SHIP HEALTHCARE HOLDINGS,INC. 1878 1 DAITO TRUST CONSTRUCTION CO.,LTD. 3382 1 Seven & I Holdings Co.,Ltd. 1881 1 NIPPO CORPORATION 3391 1 TSURUHA HOLDINGS INC. 1893 1 PENTA-OCEAN CONSTRUCTION CO.,LTD.
    [Show full text]
  • TOBAM Maximum Diversification All World Developed Ex North America USD
    TOBAM Maximum Diversification All World Developed ex North America USD 31/12/2019 Instrument Weight BP PLC 0.10% IDEMITSU KOSAN CO LTD 0.21% INPEX HOLDINGS INC 0.07% JX HOLDINGS INC 0.09% NESTE OIL OYJ 1.16% OMV AG 0.08% SANTOS LTD 0.02% SBM OFFSHORE NV 0.05% TGS NOPEC GEOPHYSICAL CO ASA 0.02% VOPAK 0.02% WOOD GROUP (JOHN) PLC 0.02% AIR LIQUIDE 0.23% AIR WATER INC 0.02% AKZO NOBEL 0.12% ALUMINA LTD 0.03% AMCOR PLC-CDI 0.08% AVON RESOURCES LTD 0.53% BORAL LTD 0.02% CHR HANSEN HOLDING A/S 0.08% DAICEL CHEMICAL INDUSTRIES 0.02% DOWA HOLDINGS CO LTD 0.01% EMS-CHEMIE HOLDING AG-REG 0.03% FLETCHER BUILDING LTD 0.02% FORTESCUE METALS GROUP LTD 0.60% GIVAUDAN-REG 0.16% HITACHI CHEMICAL CO LTD 0.03% HUHTAMAKI OYJ 0.03% ISRAEL CHEMICALS LTD 0.02% JAMES HARDIE INDUSTRIES-CDI 0.07% JFE HOLDINGS INC 0.02% KANSAI PAINT CO LTD 0.03% KURARAY CO LTD 0.03% MITSUBISHI MATERIALS CORP 0.02% NEWCREST MINING LTD 1.35% TOBAM Maximum Diversification All World Developed ex North America USD 31/12/2019 Instrument Weight NIPPON PAINT CO LTD 0.05% NIPPON PAPER INDUSTRIES CO L 0.04% NIPPON SHOKUBAI CO LTD 0.01% NISSAN CHEMICAL INDUSTRIES 0.04% NOF CORP 0.02% NORTHERN STAR RESOURCES LTD 0.66% NOVOZYMES A/S-B SHARES 0.07% OJI PAPER CO LTD 0.03% ORICA LTD 0.02% ORORA LTD 0.02% SARACEN MINERAL HOLDINGS LTD 0.32% SMURFIT KAPPA GROUP PLC 0.04% SYMRISE AG 0.04% TAIHEIYO CEMENT CORP 0.02% TAIYO NIPPON SANSO CORP 0.02% TEIJIN LTD 0.02% THYSSENKRUPP AG 0.04% TORAY INDUSTRIES INC 0.02% WIENERBERGER AG 0.02% ADP 0.04% AENA SA 0.09% ALFA LAVAL AB 0.04% ALL NIPPON AIRWAYS CO LTD
    [Show full text]
  • TOPIX100 Constituents (As of October 31, 2019) No. Code Issue No. Code Issue 1 1605 INPEX CORPORATION 51 7201 NISSAN MOTOR CO.,LTD
    TOPIX100 Constituents (as of October 31, 2019) No. Code Issue No. Code Issue 1 1605 INPEX CORPORATION 51 7201 NISSAN MOTOR CO.,LTD. 2 1878 DAITO TRUST CONSTRUCTION CO.,LTD. 52 7202 ISUZU MOTORS LIMITED 3 1925 DAIWA HOUSE INDUSTRY CO.,LTD. 53 7203 TOYOTA MOTOR CORPORATION 4 1928 Sekisui House,Ltd. 54 7267 HONDA MOTOR CO.,LTD. 5 2502 Asahi Group Holdings,Ltd. 55 7269 SUZUKI MOTOR CORPORATION 6 2503 Kirin Holdings Company,Limited 56 7270 SUBARU CORPORATION 7 2802 Ajinomoto Co.,Inc. 57 7733 OLYMPUS CORPORATION 8 2914 JAPAN TOBACCO INC. 58 7741 HOYA CORPORATION 9 3382 Seven & I Holdings Co.,Ltd. 59 7751 CANON INC. 10 3402 TORAY INDUSTRIES,INC. 60 7832 BANDAI NAMCO Holdings Inc. 11 3407 ASAHI KASEI CORPORATION 61 7974 Nintendo Co.,Ltd. 12 4063 Shin-Etsu Chemical Co.,Ltd. 62 8001 ITOCHU Corporation 13 4188 Mitsubishi Chemical Holdings Corporation 63 8002 Marubeni Corporation 14 4452 Kao Corporation 64 8031 MITSUI & CO.,LTD. 15 4502 Takeda Pharmaceutical Company Limited 65 8035 Tokyo Electron Limited 16 4503 Astellas Pharma Inc. 66 8053 SUMITOMO CORPORATION 17 4507 Shionogi & Co.,Ltd. 67 8058 Mitsubishi Corporation 18 4519 CHUGAI PHARMACEUTICAL CO.,LTD. 68 8113 UNICHARM CORPORATION 19 4523 Eisai Co.,Ltd. 69 8267 AEON CO.,LTD. 20 4528 ONO PHARMACEUTICAL CO.,LTD. 70 8306 Mitsubishi UFJ Financial Group,Inc. 21 4543 TERUMO CORPORATION 71 8308 Resona Holdings, Inc. 22 4568 DAIICHI SANKYO COMPANY,LIMITED 72 8309 Sumitomo Mitsui Trust Holdings,Inc. 23 4578 Otsuka Holdings Co.,Ltd. 73 8316 Sumitomo Mitsui Financial Group,Inc. 24 4661 ORIENTAL LAND CO.,LTD.
    [Show full text]
  • R&Co Risk-Based Japan Index
    Rothschild & Co Risk-Based Japan Index Indicative Index Weight Data as of June 30, 2021 on close Constituent Exchange Country Index Weight(%) McDonald's Holdings Co Japan L Japan 1.29 Idemitsu Kosan Co Ltd Japan 1.12 SoftBank Corp Japan 1.05 Nintendo Co Ltd Japan 0.86 Hitachi Metals Ltd Japan 0.83 Yakult Honsha Co Ltd Japan 0.82 Iwatani Corp Japan 0.81 ENEOS Holdings Inc Japan 0.79 FUJIFILM Holdings Corp Japan 0.78 KDDI Corp Japan 0.75 Toshiba Corp Japan 0.73 Calbee Inc Japan 0.73 Ajinomoto Co Inc Japan 0.72 Eisai Co Ltd Japan 0.72 Nissin Foods Holdings Co Ltd Japan 0.71 Morinaga Milk Industry Co Ltd Japan 0.70 Japan Tobacco Inc Japan 0.66 H.U. Group Holdings Inc Japan 0.66 JCR Pharmaceuticals Co Ltd Japan 0.64 MEIJI Holdings Co Ltd Japan 0.64 Yamazaki Baking Co Ltd Japan 0.63 Chugoku Electric Power Co Inc/ Japan 0.63 Nippon Gas Co Ltd Japan 0.63 PeptiDream Inc Japan 0.62 Chubu Electric Power Co Inc Japan 0.62 Seven & i Holdings Co Ltd Japan 0.62 FP Corp Japan 0.61 Pola Orbis Holdings Inc Japan 0.61 Lion Corp Japan 0.61 Shiseido Co Ltd Japan 0.60 Nippon Telegraph & Telephone C Japan 0.60 Nichirei Corp Japan 0.59 Japan Post Bank Co Ltd Japan 0.59 Kobayashi Pharmaceutical Co Lt Japan 0.59 Anritsu Corp Japan 0.58 Skylark Holdings Co Ltd Japan 0.58 Kyowa Kirin Co Ltd Japan 0.58 Lawson Inc Japan 0.58 Suntory Beverage & Food Ltd Japan 0.57 Kinden Corp Japan 0.57 MS&AD Insurance Group Holdings Japan 0.56 Shimano Inc Japan 0.56 Mitsubishi Corp Japan 0.56 Zensho Holdings Co Ltd Japan 0.56 Tokai Carbon Co Ltd Japan 0.56 Japan Post Holdings Co Ltd
    [Show full text]
  • Internet Disclosure Accompanying the Notice of Convocation the 117Th Ordinary General Meeting of Shareholders (Voluntary Disclosure)
    March 6, 2017 Internet Disclosure Accompanying the Notice of Convocation The 117th Ordinary General Meeting of Shareholders (Voluntary Disclosure) Voluntary Disclosure Relating to “3. Matters Concerning Shares Held by the Company” on the Business Report of the Company The 30 Largest Stock-Holdings of Publicly Listed Companies in the Amount on the Balance Sheet, Which the Company Holds for Purposes Other Than Realizing Direct Investment Gains ································································································· 1 Voluntary Disclosure Relating to “5. Matters Concerning Status of Corporate Governance and Directors, Audit & Supervisory Board Members and Corporate Officers of the Company” of the Business Report of the Company Criteria for Independence of “External Directors and Audit & Supervisory Board Members” ······························································································· 2 Criteria for “Important Concurrent Position” Assumed by Company’s Directors and Audit & Supervisory Board Members···························································· 6 Criteria for Stating the Relationship between the Company and the Organizations in Which the Company’s Directors and Audit & Supervisory Board Members Hold “Important Concurrent Positions” ················································································· 7 The 30 Largest Stock-Holdings of Publicly Listed Companies in the Amount on the Balance Sheet, Which the Company Holds for Purposes Other Than Realizing Direct Investment
    [Show full text]
  • Corporate Profile
    Corporate Profile Namiki Shoji Co., Ltd.: A trading company involved in marketing pharmaceuticals, compounds for drug discovery, intermediates, and health foods; and providing various biological evaluation services of compounds. Continues to be chosen as a strategic partner by numerous clients, including major Japanese pharmaceutical companies. Launched in 1974 as a company trading in raw materials of generic pharmaceuticals. We later started importing and marketing drug-discovery compounds (compounds for new drug development), first time in Japan. We continue to supply high-quality drug-discovery compounds and intermediates required at the cutting edge of new drug development, and we are holding a firm position with a top share in this field. With the support of our Pharmaceutical Dept., Drug Discovery Chemicals Dept., and Biological Research Dept., we constantly strive to supply products and services giving our clients 100% satisfaction. We hope, by means of these commercial activities, to play a significant role in radical new drug development, and our satisfaction lies in any contribution to human health. 1 Corporate Profile Greetings from the President "By mutually beneficial commercial activities, we grow together with our clients" Tatsuya Namiki Company President With our philosophy of "By mutually beneficial commercial activities, we grow together with our clients", at Namiki Shoji our aim is to expand our business energetically, in our role as the strategic partner of pharmaceutical companies. Since the founding of Namiki Shoji, we have constantly striven to develop radical new products and services to satisfy our clients, in a creative manner, rising to all challenges presented. Our business now has two pillars: Pharmaceuticals, and compounds for drug discovery.
    [Show full text]
  • Comprehensive List of Pharmaceuticals-Related Projects
    Pharmaceutical and R&D Facilities Facility Type Photo Client Location Completion Scope Wakayama/ Solid Dosage TAMURA PHARMACEUTICAL CO.,LTD. 2019 EPCV Japan Gunma/ Bio Bulk DAIICHI SANKYO CHEMICAL PHARMA CO., LTD. 2019 EPCV Japan Hyogo/ R&D Center KANAE CO.,LTD. 2019 EPC Japan API undisclosed Tohoku/Japan 2017 EPCV R&D Center JSR Corporation Tokyo/Japan 2017 EPCV API undisclosed Kitakanto/Japan 2017 EPCV Yamaguchi/ R&D Center TEIJIN PHARMA LIMITED 2015 EPCV Japan Medical Device Menicon Co., Ltd. Chubu/Japan 2014 EPCV Fukushima/ R&D Center SANWA KAGAKU KENKYUSHO CO., LTD. 2014 EPCV Japan Yamaguchi/ Medical Device Terumo Yamaguchi Corporation 2014 E+ES Japan TOYAMA CHEMICAL CO., LTD. Toyama/ Parenteral 2013 EPCV (Current name:FUJIFILM Toyama Chemical Co., Ltd.) Japan Astellas Pharma Inc. Aichi/ Bio Bulk 2013 EPCV (Current name:Micro Biopharm Japan Co.,Ltd.) Japan Kanagawa/ R&D Center Mitsubishi Tanabe Pharma Corporation 2011 EPC Japan Hiroshima/ R&D Center YASUHARA CHEMICAL CO., LTD. 2010 EPC Japan Fukushima/ API TOA EIYO LTD. 2009 EPCV Japan Gunma/ R&D Center SANDEN HOLDINGS CORPORATION 2008 EPC Japan Hyogo/ Packaging KANAE CO., LTD. 2008 EPCV Japan ASAHI GLASS CO., LTD. Chiba/ Bio Bulk 2008 EPCV (Current name:AGC Inc.) Japan 1 / 3 Iwate/ Aseptic API Shionogi & Co., Ltd. 2007 EPCV Japan Mie/ Solid Dosage Sumitomo Dainippon Pharma Co., Ltd. 2007 EPCV Japan Saitama/ Nutrition/Liquid Taisho Pharmaceutical Co., Ltd. 2007 EPCV Japan Kaketsuken Kumamoto/ Vaccine (The Chemo-sero-therapeutic Research Institute) 2006 EPCV Japan (Current name:KM Biologics Co., Ltd.) Niigata/ Vaccine Denka Seiken Co., Ltd. 2006 EPCV Japan Shizuoka/ Bio Bulk Yamaha Motor Co., Ltd.
    [Show full text]
  • Annex 1 No. of Constituents : 400 Annex 1. JPX-Nikkei Index 400 (As
    Annex 1 Annex 1. JPX-Nikkei Index 400 (As of January 6, 2014） Published on November 6, 2013 No. of constituents : 400 (Note) The No. of constituents is subject to change due to de-listing. etc. (Note) The FFW Ratio following cap-adjustment for each constituents will be announced as soon as they are decided. (Note) As for the market division, "1"=1st section, "2"=2nd section, "M"=Mothers, "J"=JASDAQ. Code Market Divison Issue Code Market Divison Issue 1417 1 MIRAIT Holdings Corporation 3765 J GungHo Online Entertainment,Inc. 1605 1 INPEX CORPORATION 3774 1 Internet Initiative Japan Inc. 1721 1 COMSYS Holdings Corporation 3861 1 Oji Holdings Corporation 1722 1 MISAWA HOMES CO.,LTD. 3941 1 Rengo Co.,Ltd. 1801 1 TAISEI CORPORATION 4004 1 Showa Denko K.K. 1808 1 HASEKO Corporation 4021 1 Nissan Chemical Industries,Ltd. 1812 1 KAJIMA CORPORATION 4042 1 TOSOH CORPORATION 1878 1 DAITO TRUST CONSTRUCTION CO.,LTD. 4045 1 TOAGOSEI CO.,LTD. 1911 1 Sumitomo Forestry Co.,Ltd. 4061 1 DENKI KAGAKU KOGYO KABUSHIKI KAISHA 1925 1 DAIWA HOUSE INDUSTRY CO.,LTD. 4063 1 Shin-Etsu Chemical Co.,Ltd. 1928 1 Sekisui House,Ltd. 4088 1 AIR WATER INC. 1951 1 KYOWA EXEO CORPORATION 4091 1 TAIYO NIPPON SANSO CORPORATION 1963 1 JGC CORPORATION 4095 1 NIHON PARKERIZING CO.,LTD. 1983 1 TOSHIBA PLANT SYSTEMS & SERVICES CORPORATION 4114 1 NIPPON SHOKUBAI CO.,LTD. 2002 1 NISSHIN SEIFUN GROUP INC. 4151 1 Kyowa Hakko Kirin Co.,Ltd. 2131 1 Accordia Golf Co.,Ltd. 4185 1 JSR CORPORATION 2212 1 YAMAZAKI BAKING CO.,LTD.
    [Show full text]